This inventor holds 6 USPTO granted patents and 3 published patent applications and 4 EPO patents. Top assignees: University of Pennsylvania, Cephalon, Inc., Eisai R&d Management Co., Ltd.. Active years: 2010-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
4 out of 2,659 
2 out of 248 
2 out of 530 
Years Active: 2010-2020
Title: Innovations in Cancer Treatment: The Contributions of Inventor Xin Cheng
Introduction
Xin Cheng, a prominent inventor based in Wallingford, PA, has made significant contributions to the field of oncology through her innovative work in antibody-drug conjugates. With a total of six patents to her name, Cheng focuses on developing targeted therapies that show promise in the treatment of cancer. Her work is instrumental in advancing the effectiveness of existing treatments and providing new avenues for addressing complex oncological challenges.
Latest Patents
Among her latest inventions, Cheng has developed "Eribulin-based antibody-drug conjugates and methods of use." These inventions involve linker toxins and antibody-drug conjugates that specifically bind to human oncology antigen targets, such as folate receptor alpha. The integration of an eribulin drug moiety allows these conjugates to be internalized into target antigen-expressing cells, enhancing their effectiveness in treating cancer. Additionally, her disclosures detail methods and compositions for administering these antibody-drug conjugates in clinical settings, further showcasing her innovation in the fight against cancer.
Career Highlights
Cheng has built her career in esteemed organizations, including the University of Pennsylvania and Cephalon, Inc. Her tenure in these institutions has provided her with a solid foundation for research and has enabled her to contribute significantly to advancements in therapeutic strategies for cancer treatment.
Collaborations
Throughout her career, Xin Cheng has collaborated with respected colleagues such as Mark I. Greene and Ramachandran Murali. These collaborations have played a crucial role in pooling expertise and resources towards developing effective cancer therapies, amplifying the impact of her inventions.
Conclusion
Xin Cheng's innovative research in eribulin-based antibody-drug conjugates represents a remarkable stride in cancer treatment. Through her patents and collaborations, she continues to drive progress in the field, offering hope for more effective therapeutic solutions. As her work evolves, it undoubtedly paves the way for future innovations in oncological medicine, reaffirming the importance of her contributions as an inventor.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile